UBS Group
OKUR

UBS Group’s OnKure Therapeutics OKUR Stock Holding History

UBS Group’s Portfolio OKUR Stock Details OKUR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$14.1K Buy
3,395
+2,187
+181% +$6.75K ﹤0.01% 8195
2025
Q4 		$3.5K Buy
1,208
+1,003
+489% +$3K ﹤0.01% 9006
2025
Q3 		$564 Buy
205
+24
+13% +$59 ﹤0.01% 9624
2025
Q2 		$433 Sell
181
-99
-35% -$260 ﹤0.01% 9827
2025
Q1 		$1.2K Sell
280
-1,933
-87% -$10.9K ﹤0.01% 9554
2024
Q4 		$19K Buy
2,213
+2,094
+1,760% +$31.7K ﹤0.01% 7911
2024
Q3 		$2.02K Sell
119
-1,000
-89% -$14.8K ﹤0.01% 8517
2024
Q2 		$16.9K Sell
1,119
-69
-6% -$1.17K ﹤0.01% 7412
2024
Q1 		$19.7K Sell
1,188
-457
-28% -$7.54K ﹤0.01% 6933
2023
Q4 		$26.3K Sell
1,645
-1,227
-43% -$76.5K ﹤0.01% 6927
2023
Q3 		$219K Sell
2,872
-3,484
-55% -$237K ﹤0.01% 5309
2023
Q2 		$417K Buy
6,356
+1,060
+20% +$85.4K ﹤0.01% 4977
2023
Q1 		$317K Sell
5,296
-459
-8% -$16.6K ﹤0.01% 5035
2022
Q4 		$134K Sell
5,755
-5
-0.1% -$133 ﹤0.01% 5819
2022
Q3 		$193K Buy
5,760
+305
+6% +$10K ﹤0.01% 5117
2022
Q2 		$145K Buy
5,455
+5,348
+4,998% +$124K ﹤0.01% 5149
2022
Q1 		$3K Sell
107
-159
-60% -$8.9K ﹤0.01% 9503
2021
Q4 		$23K Buy
+266
New +$19.5K ﹤0.01% 7689

Other funds holding OKUR

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $460M AUM 261.77% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

UBS Group's OKUR Position: Q1 2026 in Review

UBS Group increased its OnKure Therapeutics (OKUR) stake by 181% in Q1 2026, buying an estimated $6.75K and bringing the position to 3,395 shares worth $14.1K. The position accounts for ﹤0.01% of the portfolio, ranked #8195.

UBS Group first reported a position in OKUR in Q4 2021 and has held it in 18 quarters since. The position peaked at $417K in Q2 2023. 51 funds tracked by Wall St. Rank hold OKUR as of Q1 2026.

  • UBS Group held 3,395 shares of OnKure Therapeutics worth $14.1K as of Q1 2026.
  • UBS Group bought 2,187 OnKure Therapeutics shares in Q1 2026, an estimated $6.75K.
  • OnKure Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #8195 holding.
  • UBS Group first reported a position in OnKure Therapeutics in Q4 2021 and has held it in 18 quarters since.
  • UBS Group's OnKure Therapeutics position peaked at $417K in Q2 2023.
  • 51 funds tracked by Wall St. Rank held OnKure Therapeutics as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.